Sign InEli Lilly Stock Analysis: Positive Momentum Amid Drug Approval Expectations
Summary
Eli Lilly and Company (LLY) closed its trading session on October 23, 2023, with a price of $576.65, down by 1.37%, but with positive technical and fundamental analysis, including high expectations for forthcoming obesity-drug approvals, it is categorized as a 'Buy' with the potential for increased prices on October 24, 2023.
Introduction
Eli Lilly and Company (LLY), a major drug manufacturing company listed on the NYSE, closed its trading session on October 23, 2023, with a price of $576.65, down by 1.37%. This technical and fundamental analysis evaluates the current situation of the stock and makes predictive assessments for the upcoming trading sessions.
Technical Analysis
The stock's Relative Strength Index (RSI) is at 69, implying that the stock is approaching the overbought region, potentially signifying that its recent rally might be slowing down. The 50-day moving average comes in at $564.87, showing a short-term bullish trend as the current price is higher than the average. The longer-term 200-day moving average is at $436.66 and since the current price is well above this mark, it also suggests a long-term bullish sentiment.
On the downside, support lies at $575.66, very near to the last close. Resistance is higher at $586.46. The ATR at 2.75 suggests good volatility, potentially offering opportunities for intra-day traders. The MACD (3-month) is at 5.82, signaling a bullish market sentiment.
Fundamental Analysis
Eli Lilly has a high P/E ratio of 80.2, which indicates that the market has high expectations of the firm’s future growth. Its robust EPS of $7.19, indicates a strong profit generation capacity.
The company has a colossal market capitalization of approximately $547.41 billion, showing Eli Lilly's substantial size and influence. The significant trading volume of around 2.78 million shares further underscores Eli Lilly's high liquidity.
The projected discounted cash flow (DCF) is around $578.93 which is close to the last closing price, pointing towards a fair valuation.
Broker recommendations unanimously suggest a buying sentiment with 15 buy recommendations and no hold or sell recommendations. The consensus for the stock is "Buy".
News Impact
There are high expectations tied to the Eli Lilly's forthcoming announcements about obesity-drug approval. This announcement could potentially be a massive catalyst to the company's revenue growth for the next decade. Notably, the firm, along with Novo Nordisk, has commenced testing weight loss drugs for children, opening a new market segment.
Predictions
Considering the stock's current momentum and pending news about drug approvals, the price might increase during the next trading day, October 24, 2023. The high analyst's target is $673, which could potentially be achieved in the upcoming week, but that would require significant positive news flow and market sentiment.
Evaluation
Given the favorable technical and fundamental analysis, and considering the overwhelmingly positive anticipation about potential drug approvals, Eli Lilly is currently categorized as a 'Buy'. However, investors must incorporate their risk profile and investment objectives before making a decision. Monitoring the company's announcements about drug approvals and testing will be key. Nevertheless, Eli Lilly appears to offer an appealing opportunity for potential investors given its strong growth prospects.
